VANCOUVER, British Columbia, May 30, 2018 (GLOBE NEWSWIRE) -- NeutriSci International Inc. ("NeutriSci") (TSX-V:NU) (OTCQB:NRXCF) (FRANKFURT:1N9) the innovator and pioneer behind neuenergy®, and Nutritional High International Inc. (“Nutritional High) (CSE:EAT) (OTCQB:SPLIF) (FRANKFURT:2NU), are pleased to announce the entry into a binding Memorandum of Understanding (“MOU”) to develop, manufacture and distribute THC and CBD infused sublingual tablets utilizing NeutriSci’s patent pending technology, proprietary ingredients and formulations.
Subject to the negotiation of a definitive agreement, NeutriSci and Nutritional High will develop products which will be manufactured and distributed by Nutritional High in US states which permit the sale of cannabis infused products. The tablets will combine the benefits of NeutriSci and Nutritional High’s existing technologies and ingredient mixes. The tablets will be quick dissolving and will offer a measured dose of pure THC or CBD oil, combined with the powerful bio-availability & antioxidant properties of pterostilbene. The tablets will be flavored and optimized for efficacy and taste with zero-sugar. Initial manufacturing will be carried out in Nutritional High’s manufacturing facilities in Sacramento, California and Green Therapeutics LLC facilities in Las Vegas, Nevada, with sales and distribution expected to begin in Q3-2018.
As previously announced, NeutriSci has filed a United States provisional patent application (United States Provisional Patent No. 62/628,735; Compositions Comprising Co-crystals of Stilbenoids and Cannabinoids) relating to compositions comprising pterostilbene and other stilbenoids in formulations which improve the dissolution rate and bioavailability of cannabinoid compounds.
NeutriSci’s CEO, Glen Rehman stated, “This MOU establishes the first product manufacturing and distribution deal utilizing our patent pending technologies. Together with Nutritional High, we are very excited for the launch of these quick dissolving THC and CBD tablets. This agreement represents a significant milestone in the cannabinoid industry.”
Nutritional High CEO, Jim Frazier stated, “We are excited to work with NeutriSci to develop and launch proprietary THC and CBD infused sublingual tablets. NeutriSci’s formulations combined with our oil should make for a very effective cannabis energy product.”
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
About Nutritional High International Inc.
Nutritional High is focused on developing, manufacturing and distributing products and nationally recognized brands in the marijuana-infused products industry, including edibles and oil extracts for nutritional, medical and adult recreational use. The company works exclusively through licensed facilities in jurisdictions where such activity is permitted and regulated by state law.
For updates on the company's activities and highlights of the company's press releases and other media coverage, please follow Nutritional High on Facebook, Twitter, Instagram and Google+ or visit www.nutritionalhigh.com.
See Nutritional High’s press released dated March 13, 2018 relating to its proposed acquisition of Green Therapeutics LLC.
For further information, please contact:
David Posner
Chairman of the Board
Nutritional High International Inc.
647-985-6727
Email: dposner@nutritionalhigh.com
NEITHER THE TSX VENTURE EXCHANGE, THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.
Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.